Search clinical trials for: MK-0616

Total 1802 results

Merck Sharp & Dohme LLC

Completed

A Study of MK-0616 in Participants With Moderate Renal Impairment (MK-0616-007)

Moderate Renal Impairment

United States
Merck Sharp & Dohme LLC

Completed

Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001)

Multiple Myeloma | Solid Tumor
Merck Sharp & Dohme LLC

Completed

Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009)

Neoplasm
Merck Sharp & Dohme LLC

Terminated

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Neoplasms Malignant
Merck Sharp & Dohme LLC

Completed

A Dose-finding Study of Dalotuzumab in Subjects With Advanced Solid Tumors (MK-0646-002)

Advanced Solid Tumors
Merck Sharp & Dohme LLC

Completed

MK-0616 (Oral PCSK9 Inhibitor) Renal Impairment Study 2 (MK-0616-020)

Hypercholesterolaemia

United States
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017) CORALreef HeFH

Hypercholesterolemia | Familial Hypercholesterolemia

United States, Australia, Brazil, Canada, Chile, Colombia, Czechia, Finland, Hong Kong, Hungary, Israel, Netherlands, New Zealand, Norway, Singapore, Spain, Taiwan
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids

Hypercholesterolemia | Familial Hypercholesterolemia

United States, Taiwan, Israel, Argentina, Japan, Korea, Republic of, Turkey, Colombia, China, Mexico, Germany, Italy, South Africa, Spain
Merck Sharp & Dohme LLC

Recruiting

MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

Arteriosclerosis | Hypercholesterolaemia

United States, Taiwan, Canada, Israel, New Zealand, Hong Kong, Argentina, Korea, Republic of, Turkey, Australia, Chile, Brazil, Japan, Colombia, China, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study of the Efficacy and Safety of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

Hypercholesterolemia | Familial Hypercholesterolemia

United States, Germany, Japan, Korea, Republic of, Mexico, Norway, Turkey, United Kingdom
Memorial Sloan Kettering Cancer Center
Merck Sharp & Dohme LLC

Completed

Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET)

Neuroendocrine Tumors | Metastatic Neuroendocrine Tumors

United States
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Recovery From dNMB Using Different Sugammadex Doses in Elderly Patients Undergoing Robot-assisted Prostatectomy (RECIR)

Prostate Cancer | Neuromuscular Blockade

Italy
Merck Sharp & Dohme LLC

Completed

Comparison of the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616; Org 25969) in Elderly Participants With Adult Participants (MK-8616-029)

Anesthesia, General
NorthShore University HealthSystem

Recruiting

Evaluating Outcomes in Cardiac Surgery Patients Who Receive Sugammadex vs. Placebo

Surgery

United States
Merck Sharp & Dohme LLC

Completed

The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)

Breast Cancer
Merck Sharp & Dohme LLC

Completed

Relation Between TOF-Watch® SX and a Peripheral Nerve Stimulator After 4.0 mg.Kg-1 Sugammadex (P05698)

Neuromuscular Blockade
Merck Sharp & Dohme LLC

Completed

A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Japanese Participants. Part A (P05957)

Anesthesia, General
Merck Sharp & Dohme LLC

Completed

A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)

Anesthesia, General
Merck Sharp & Dohme LLC

Completed

A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013)

Breast Cancer
Merck Sharp & Dohme LLC

Completed

Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767)

Anesthesia | Neuromuscular Blockade
Merck Sharp & Dohme LLC

Completed

A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)

Breast Cancer
University of Kansas
Merck Sharp & Dohme LLC

Completed

MK-0646 Insulin Growth Factor 1 Receptor Antibody in Stage IIIb or IV Metastatic Non-Squamous Lung Cancer (IMPACT)

Non Small Cell Lung Cancer

United States
AlaMab Therapeutics (Shanghai) Inc.

Recruiting

Study to Evaluate the Safety and Pharmacokinetics of ALMB-0166 in Patients With Acute Spinal Cord Injury

Acute Spinal Cord Injury

China
Constellation Pharmaceuticals
The Leukemia and Lymphoma Society

Completed

A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma

Lymphoma
Merck Sharp & Dohme LLC

Completed

A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)

Carcinoma, Non-small-cell Lung
Constellation Pharmaceuticals
The Leukemia and Lymphoma Society

Completed

A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma

Multiple Myeloma
University of Texas Southwestern Medical Center

Withdrawn

Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors

Peripheral Nerve Tumors

United States
Constellation Pharmaceuticals

Completed

Study Evaluating Food Effect and QTc in Patients With Advanced Malignancies

Solid Tumor | Advanced Malignancies | Hematological Malignancy

Spain, United States, Georgia
Kissei Pharmaceutical Co., Ltd.

Completed

Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes

Dry Eye Syndromes

Japan
Kezar Life Sciences, Inc.

Completed

Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM.

Dermatomyositis | Polymyositis

United States
Merck Sharp & Dohme LLC

Terminated

A Trial of Dalotuzumab in Combination With Irinotecan Versus Cetuximab and Irinotecan for Participants With Metastatic Rectal Cancers (mRC) (MK-0646-025)

Rectal Neoplasms
Merck Sharp & Dohme LLC

Completed

A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

Type 2 Diabetes Mellitus
Centrexion Therapeutics

Completed

A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects

Pain | Chronic Pain | Nociceptive Pain

United States
Merck Sharp & Dohme LLC

Completed

Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023)

Anesthesia, General
Merck Sharp & Dohme LLC

Completed

A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)

Breast Neoplasms
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Betta Pharmaceuticals Co., Ltd.

Active, not recruiting

The Absorption, Metabolism and Excretion of [14C]D-0316 in Human

Advanced or Metastatic Non-small Cell Lung

China
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
Shanghai Antengene Corporation Limited

Terminated

A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors (REACH)

Advanced Solid Tumors

China
Kezar Life Sciences, Inc.

Withdrawn

A Phase 2 Study to Evaluate the Safety and Efficacy of KZR-616 in Patients With AIHA and ITP (MARINA)

Immune Thrombocytopenia | Autoimmune Hemolytic Anemia

Poland, United States, Australia, Italy, Russian Federation
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)

Polysomnography
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of MK-8266 (MK-8266-001)

Hypertension
Merck Sharp & Dohme LLC

Completed

Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)

Solid Tumors

United States, Canada, Switzerland
Merck Sharp & Dohme LLC

Completed

Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)

Advanced Cancer
Merck Sharp & Dohme LLC

Recruiting

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

HIV | HIV Pre-exposure Prophylaxis

United States, South Africa, Israel
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study of MK-3614 (MK-3614-002)

Hypertension
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Withdrawn

A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)

Asthma
Shanghai Antengene Corporation Limited

Terminated

A Study to Evaluating the Pharmacokinetics, Safety, and Efficacy of ATG 016 Monotherapy in IPSS-R Intermediate Risk and Above Myelodysplastic Syndrome (MDS) (HATCH)

Myelodysplastic Syndrome

China

3

Subscribe